Sign in
Taking people in United StatesPhase 1/2

Gene Therapy Tested in Blood Cancers That Return or Do Not Respond

Tests VNX-101 gene therapy in people with relapsed or refractory CD19-positive blood cancers.

Key facts

Who runs it
Vironexis Biotherapeutics Inc.
Where
Chapel Hill, Columbus, Denver, Duarte, Houston, Jacksonville, Los Angeles, Nashville, Portland, Rochester, and Valhalla, United StatesSee the 11 sites
Trial code
Registry title
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Status
Recruiting
Phase
Phase 1/2
People taking part
32 people, planned
Started
30 May 2025
Expected to end
Sept 2031
Type of study
Interventional
Treatments tested
  • Dose Level 1, VNX-101
  • Dose Level 2, VNX-101
  • Dose Level 3, VNX-101
  • Dose Level 4, VNX-101
Record updated
26 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with leukemia or lymphoma that has come back or has not responded to treatment, and whose cancer cells carry the CD19 marker.

Age
Part 1: 18-90 years. Part 2: 13-90 years.
Sex
All sexes can join.
Disease stage
Relapsed or refractory CD19-positive leukemia or lymphoma, as defined in the protocol.
Earlier treatment
Chemotherapy must not have been given within the protocol-specified time before joining.
Biomarker or test result
CD19-positive expression is required. A specific AAV capsid total antibody result is also required, per the protocol.

Main reasons for not taking part

  • Liver damage (AST or ALT above 2x the upper limit of normal)
  • History of thrombotic microangiopathy or cardiomyopathy, or signs of sensory neuropathy
  • Pregnant or nursing women
  • Acute graft versus host disease grade 2-4, or chronic graft versus host disease of any grade
  • History of allergy or toxicity related to corticosteroids

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age: Part 1: 18-90 years of age, Part 2: 13-90 years of age
  • Relapsed or refractory CD-19 positive leukemia or lymphoma as defined in the protocol
  • CD19-positive expression
  • AAV specified capsid total antibody per protocol requirement
  • Protocol-specified ranges for renal, liver, cardiac and pulmonary function
  • Protocol-specified ranges for hematology parameters

Who cannot take part

  • Chemotherapy given within the protocol-specified discontinuation timelines; Other Inclusion/Exclusion criteria to be applied per protocol
  • History of thrombotic microangiopathy or cardiomyopathy, or evidence of sensory neuropathy
  • Acute Graft versus Host Disease (GvHD): Grade 2-4 or chronic GvHD of any grade
  • History of hypersensitivity to corticosteroids or history of corticosteroid-related toxicity
  • Hepatoxicity (AST or ALT > 2x upper limit of normal)
  • Pregnant or nursing (lactating) women

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 13 and 90 years old?

Where in United States

  • University of North Carolina at Chapel Hill/ University of North Carolina Medical CenterChapel Hill, United StatesContact: Lacey Williams, MDTaking people
  • The Ohio State University -Wexner Medical CenterColumbus, United StatesContact: Gregory Behbehani, MD, PhDTaking people
  • Colorado Blood Cancer InstituteDenver, United StatesContact: Allen RehaTaking people
  • City of HopeDuarte, United StatesContact: Anthony Stein, MDTaking people
  • University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: Nicholas J Short, MDTaking people
  • Mayo Clinic, Clinical Trials Referral OfficeJacksonville, United StatesContact: Allen RehaTaking people
  • Valkyrie Clinical TrialsLos Angeles, United StatesContact: Myo ZawTaking people
  • TriStar BMTNashville, United StatesContact: Stephen Strickland, MDTaking people
  • Oregon Health Science UniversityPortland, United StatesContact: Knight Cancer Institute Clinical TrialsTaking people
  • Mayo Clinic, Clinical Trials Referral OfficeRochester, United StatesContact: Allen RehaTaking people
  • New York Medical CollegeValhalla, United StatesContact: Mitchell Cairo, MDTaking people

About the trial

What the trial wants to find out

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

The group in the trial

  • Group 1/Group 2/Group 3/Group 4Treatment being tested

    Treatment: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, and Dose Level 4, VNX-101

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Plain-language title
Gene Therapy Tested in Blood Cancers That Return or Do Not RespondGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06533579, who can take part
Record updated
26 October 2026